Evaxion's Personalized Melanoma Vaccine Shows Sustained Three-Year Responses in Phase 2 Trial

Evaxion A/S reported three-year clinical data from its Phase 2 trial of personalized cancer vaccine EVX-01 for advanced melanoma. All patients maintained clinical responses with no tumor progression, even when EVX-01 was a stand-alone therapy in the third year. These findings, building on a 75% Objective Response Rate, will be presented at ESMO 2026, suggesting potential long-term efficacy for this treatment.